(CercleFinance.com) – Johnson & Johnson announced that nine oral presentations will be made at the 2023 congress of the European Society of Medical Oncology (ESMO).
A total of 19 studies, including seven late-breaking abstracts, will present new data and updates on lung cancer, bladder cancer and prostate cancer.
Three phase III studies of RYBREVANT® (amivantamab-vmjw) (MARIPOSA, MARIPOSA-2 and PAPILLON) in EGFR-mutated lung cancer achieved statistically and clinically significant progression-free survival endpoints.
New findings from the novel investigational intravesical delivery systems TAR-200 and TAR-210 highlight the potential for transformational results in the treatment of bladder cancer.
“The data and results premiered at this year’s ESMO represent our determination to advance the science of oncology and set new standards for innovation in the treatment of solid malignancies,” said Peter Lebowitz, MD. , PhD, Global Therapeutic Area Head, Oncology, Janssen Research & Development.
‘The evolution of targeted therapies in oncology presents a promising avenue to bring the latest innovations to patients,’ said Martin Vogel, Head of Oncology EMEA Therapeutic Area at Janssen-Cilag.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Are you following this action?
Receive all the information on JOHNSON & JOHNSON in real time: